GenScript ProBio, a US-based global Contract Development and Manufacturing Organisation (CDMO), announced on Wednesday that it has agreed to set up a strategic partnership with RVAC Medicines Pte. Ltd., a Singapore-based biotechnology company focusing on the development and commercialisation of messenger RNA (mRNA) therapeutics and vaccines.

The companies are partnering for the production of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with a collaboration for future therapeutic pipelines.

Under the partnership, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. This partnership is intended to enable RVAC Medicines to accelerate its clinical manufacturing of mRNA-based COVID-19 vaccine, RVM-V001, and future mRNA-based vaccines targeting infectious diseases such as Respiratory syncytial virus (RSV) and Clostriodioides difficile infection (CDI).

RVAC Medicines is to continue to partner with GenScript ProBio to support its mRNA initiatives for both clinical-stage development and commercial stage.